Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

View the 50 largest pharmaceutical companies in the world listings here

Takeda

Takeda Pharmaceutical

Rank: 11

Tokyo, Japan
www.takeda.com

2020 Revenues ($USD) : $29,948,845,895
2020 Revenues (foreign currencies) : JP¥3,197,800,000,000
2020 R&D spend : $4,268,773,519
2020 Number of Employees : 47,495
Fiscal Year End : 3/31/2021
Key People : Christophe Weber, representative director, president and CEO; Masato Iwasaki, director, Japan general affairs; Dr. Andrew S. Plump, director, president, R&D; Costa Saroukos, director/CFO; Marcello Agosti, global business development officer; Teresa Bitetti, president, global, oncology business unit; Lauren Duprey, chief human resources officer; Milano Furuta, president, Japan pharma business unit; Gerard Greco, global quality officer; Julie Kim, resident, plasma-derived therapies business unit; Mwana Lugogo, chief ethics and compliance officer; Ricardo Marek, president, growth and emerging markets business unit; Yoshihiro Nakagawa, global general counsel; Takako Ohyabu, chief global corporate affairs officer; Giles Platford, president, Europe and Canada business unit; Koki Sato, corporate strategy officer and chief of staff; Ramona Sequeira, president, U.S. business unit and global portfolio commercialization; Rajeev Venkayya, president, global vaccine business unit; Thomas Wozniewski, global manufacturing and supply officer

The Japanese pharma giant works with health providers and patients in roughly 80 countries. Its research efforts are focused on four therapeutic areas: oncology, rare genetic and hematology, neuroscience, and gastroenterology. Takeda also makes targeted R&D investments in Plasma-Derived Therapies and Vaccines. The company posted in February that it has a pipeline of roughly 40 clinical-stage new molecular entities (NMEs) that is beginning to deliver. They include its TAK-721, which is under priority review at U.S. FDA. TAK-721 remains on track to be the first FDA-approved agent to treat eosinophilic esophagitis. Takeda is also seeking EU regulatory approval for its tetravalent dengue vaccine candidate (TAK-003). –CN

Takeda building

[Takeda Development Center Asia in Singapore. Image courtesy of Takeda.]

Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50